|Class Period:||Jul-31-14 to Jun-15-15|
|Lead Plaintiff Deadline:||Aug-9-15|
|Court:||Northern District of California|
Avalanche is a biotechnology company engaged in the development of gene therapies for patients with various ophthalmic diseases. According to the complaint, on June 15, 2015, Avalanche held a conference call to discuss their Phase IIa trial results concerning a gene therapy treatment for wet age-related macular degeneration. During the call Avalanche stated that the study was not designed to demonstrate statistically significant differences between the active and control groups. As a result, shares dropped over 56% the following day to end at $17.05 on June 16, 2015.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.